Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. Catalent Biologics Emeryville, CA site, formerly the startup company Redwood Bioscience, has developed a proprietary approach for site-specific bioconjugation to produce next-generation antibody-drug conjugates (ADCs). This technology, termed SMARTag®, is based on use of the aldehyde-tag site-specific protein modification technology and Catalent's novel conjugation chemistry and proprietary, stable linkers. SMARTag is a clinical-stage technology that was named Runner Up for Best Platform at the 2022 World ADC Awards in San Diego, CA. The Catalent Biologics Emeryville site comprises a close-knit team of scientists working cross-functionally with each other to nimbly achieve our goals and milestones. We are a research site, working to develop therapeutic ADC drug candidates for clinical testing. We also continuously strive to improve and expand our technology platform. The team has a focus on publishing papers and filing intellectual property to contribute to the exciting and dynamic field of bioconjugation and drug conjugates.